Author/Authors :
Aghamohammadzadeh، Naser نويسنده Department of Endocrinology, Tabriz University of Medical Sciences, Tabriz, Iran , , Dastranj Tabrizi، Ali نويسنده Associate Professor of Pathology, Womens Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. , , Niafar، Mitra نويسنده Department of Endocrinology, Tabriz University of Medical Sciences, Tabriz, Iran , , Najafipor، Farzad نويسنده Department of Endocrinology, Tabriz University of Medical Sciences, Tabriz, Iran ,
Abstract :
Background: To evaluate the efficacy of adding the glutazone to maximum dose of sulfonylurea and metformin in patients with poorly controlled type 2 diabetes.
Methods: Ninety six patients with type 2 diabetes who had failed medical therapy with maximal-dosage of metformin and glibenclamide received glutazone. Fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C, cholesterol and HDL levels were assessed at baseline three months later.
Results: Ninety-six patients with type 2 diabetes (74 women and 22 men) with the mean age of 55.7±9.9 years were studied. Significant reduction was seen in fasting blood sugar (FBS), 2 hours postprandial (2hpp) glucose, hemoglobin A1C and triglyceride levels three months after adding glutazone to therapeutic regimen (p < 0.0005). There was not a significant rise in cholesterol and HDL levels before and after the new therapy.
Conclusion: The results show that the combination of glutazone, metformin and glibenclamide may result in better control of glycemic status in diabetic patients resistant to oral first-line agents.
